Action 61Y MARINUS PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Marinus Pharmaceuticals, Inc. BOERSE MUENCHEN

Actions

61Y

US56854Q2003

Marché Fermé - BOERSE MUENCHEN
Autres places de cotation
 21:43:23 28/06/2024 		Varia. 5j. Varia. 1 janv.
1,13 EUR -3,42 % Graphique intraday de Marinus Pharmaceuticals, Inc. -11,02 % -88,64 %
17/06 Mise à jour sectorielle : Les actions du secteur de la santé en baisse lundi avant le marché MT
17/06 Les plus mauvais élèves du prémarché MT

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before August 5, 2024 to Discuss Your Rights - MRNS
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schal Law Firm
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
BU
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
BU
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
BU
Marinus Pharmaceuticals : Corporate Overview Slide Deck
PU
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
BU
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Marinus Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - MRNS
NE
Pomerantz Law Firm Announces the Filing of a Class Action Against Marinus Pharmaceuticals, Inc. - MRNS
PR
Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
BU
Marinus Pharmaceuticals, Inc. Stockholders with Large Losses Should Contact Robbins LLP About Their Rights in Connection with the MRNS Class Action Lawsuit
BU
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
PR
MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit
PR
MRNS Bronstein, Gewirtz & Grossman LLC Announces that Marinus Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
BU
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Marinus Pharmaceuticals, Inc. (MRNS) Investors
BU
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action MRNS
  4. Action 61Y
  5. Actualités Marinus Pharmaceuticals, Inc.
  6. Communiqués